YAMAMOTO Kazuhiko | The University of Tokyo
スポンサーリンク
概要
関連著者
-
MIYASAKA Nobuyuki
Tokyo Medical and Dental University
-
YAMAMOTO Kazuhiko
The University of Tokyo
-
KAWAI Shinichi
Toho University Omori Medical Center
-
TAKEUCHI Tsutomu
Saitama Medical Center/School
-
Nishimoto Norihiro
Wakayama Medical University
-
Kawai Shinichi
Toho University
-
HASHIMOTO Jun
Osaka University Graduate School of Medicine
-
GARNERO Patrick
Inserm Research Unit 664 and Synarc
-
YOSHIKAWA Hideki
Osaka University Graduate School of Medicine
-
NISHIMOTO Norihiro
Laboratory of Immune Regulation, Wakayama Medical University
-
Nishimoto Norihiro
Laboratory Of Immune Regulation Graduate School Of Frontier Biosciences Osaka University
-
Nishimoto Norihiro
Department Of Medical Science I School Of Health And Sport Siences Osaka University
-
Takeuchi Tsutomu
Keio Univ. School Of Medicine Tokyo Jpn
-
Yoshikawa Hideki
Department Of Orthopaedics Osaka University Graduate School Of Medicine
-
Nishimoto N
Laboratory Of Immune Regulation Osaka University Graduate School Of Frontier Bioscience
-
Van Der
University Hospital Maastricht
-
Garnero Patrick
Inserm Research Unit 664
-
Nishimoto Norihiro
Laboratory Of Immune Regulation
-
KISHIMOTO Tadamitsu
Osaka University
-
VAN DER
Leiden University Medical Center
-
Van Der
Leiden Univ. Leiden Nld
-
Azuma Junichi
Osaka University
-
Yoshikawa Hideki
Department Of Orthopaedic Surgery Osaka University Graduate School Of Medicine
-
YAMAMOTO Kazuhiko
University of Tokyo
-
Hashimoto Jun
Department Of Orthopaedic Surgery Osaka University Graduate School Of Medicine
-
Azuma Junichi
Osaka Pharmaceutical Research Clinic:faculty Of Pharmaceutical Science Osaka University
-
Van Der
Leiden Institute Of Chemistry Leiden University
-
TANAKA Yoshiya
University of Occupational and Environmental Health
-
Kawai Shinichi
Division Of Rheumatology Department Of Internal Medicine (omori) School Of Medicine Faculty Of Medicine
-
YAMAMOTO Kazuhiko
Tokyo University
著作論文
- A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs
- Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI) : significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition
- Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiograp
- Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs-a multicenter, double-blind, parallel-group trial